From Multiomics Biomarker Discovery to AI‐Driven Clinical Translation: Precision Early Detection of Pulmonary Arterial Hypertension in Older Adults Across G20 Nations
International Journal of Clinical Practice · 2026-01 · 2026 (1)
DOI: 10.1155/ijcp/6652927 ↗Abstract
Background Pulmonary arterial hypertension (PAH) shows significant clinical variability in older adults. Standard diagnostic methods often detect the disease late, creating a need for multiomics‐based biomarker discovery. Integrating these with artificial intelligence (AI) can improve early screening and risk stratification, helping G20 countries tackle public health challenges linked to aging. Methods Using Global Burden of Disease 2023 data and multiomics evidence from adults aged 55 and older in G20 nations, we applied machine learning to assess age–sex disease burden patterns. Deep learning models assessed circulating biomarkers—microRNA profiles, plasma proteomic markers (GDNF and GDF‐15), and metabolomic signatures—for predicting disease onset and progression across sociodemographic index (SDI) regions. Results In 2023, the age‐standardized PAH incidence rate among adults ≥ 55 in G20 countries was 1.33 per 100,000 people. AI analysis identified exosomal miR‐223‐3p and mitochondrial metabolic fingerprints as key early‐warning signals, accumulating notably in ages 70–74. Elevated GDF‐15 and IL‐6 were linked to diagnostic delays in low‐SDI areas (SHAP weight = 0.24). A metabolomic ratio of dodecatrienoic acid to sphingosine predicted PAH risk in women (AUC = 0.87). An XGBoost model incorporating these biomarkers enabled accurate risk stratification in high‐burden countries such as India and Mexico (AUC = 0.92). Conclusions We systematically identified and validated novel multiomics biomarkers associated with aging and PAH. These support clinical translation via blood‐based diagnostic kits using exosomal miRNA and proteomic markers, individualized prognostic models with metabolomic data, and tailored precision prevention strategies adaptable to diverse health systems—potentially enabling earlier intervention and improved PAH management.
EUVIMED